Related Experiment Videos
[Concurrent or sequential treatment for osteoporosis with PTH and alendronates]
1Research Institute and Practice for Involutional Diseases.
Clinical Calcium
|March 19, 2005
Summary
Parathyroid hormone (PTH) treatment for osteoporosis improves lumbar bone density but can decrease cortical bone and lead to withdrawal effects. Combining PTH with alendronate prevents these drawbacks, offering a powerful fracture prevention strategy.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Context:
- Osteoporosis treatment often involves parathyroid hormone (PTH).
- PTH stimulates bone formation and resorption, with varied effects on different bone sites.
- PTH therapy can lead to decreased bone mineral density (BMD) at cortical sites and a withdrawal phenomenon after cessation.
Purpose:
- To evaluate the efficacy of combined or sequential treatment with PTH and alendronate for osteoporosis.
- To address the limitations of PTH monotherapy, specifically concerning cortical bone and post-treatment BMD.
- To determine if this combined approach mitigates the negative effects of PTH withdrawal.
Summary:
- Concurrent or sequential administration of PTH and alendronate demonstrated significant increases in BMD across all measured bone sites.
- This combined treatment strategy effectively prevented the reduction in lumber BMD typically observed after PTH cessation.
- No withdrawal phenomenon was noted in BMD following the cessation of PTH administration in the combined treatment groups.
Impact:
- Sequential or concurrent PTH and alendronate treatment represents a promising therapeutic strategy for osteoporosis.
- This approach may offer a more robust and sustained improvement in bone health compared to PTH alone.
- It holds potential as a powerful tool for preventing osteoporotic fractures by improving overall bone mineral density and stability.